REVELATION PHARMACY, LLC – Trademark Portfolio
Entity Type: 16
REVELATION PHARMACY, LLC holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 2 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include CONSULTRX. The owner is based in Englewood, CO.
9777 Pyramid Court
Englewood, CO 80112
Showing of trademarks Trademarks
Trademark Classifications
REVELATION PHARMACY, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does REVELATION PHARMACY, LLC have?
REVELATION PHARMACY, LLC has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.
What trademark classes does REVELATION PHARMACY, LLC file in?
REVELATION PHARMACY, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are REVELATION PHARMACY, LLC's most well-known trademarks?
REVELATION PHARMACY, LLC's registered trademark portfolio includes well-known marks such as CONSULTRX. These are among 1 currently registered trademark in the portfolio.
What is REVELATION PHARMACY, LLC's trademark registration success rate?
REVELATION PHARMACY, LLC has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.